{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"5.52","value":"7.6"}]}],"title":"Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"6.51","value":"9.7"}]}],"title":"Day 8"}],"denoms":[{"counts":[{"groupId":"OG000","value":"27"}],"units":"Participants"}],"description":"Cmax is defined as the maximum observed drug concentration observed in plasma over all PK sample concentrations. It will be obtained from the Cmax parameter calculated by WinNonlin®. If there is no measurable concentration in the subject's PK profile, then Cmax will be missing for that subject. Cmax will be reported in units of ng/mL.","dispersionType":"Standard Deviation","groups":[{"description":"Participants received panobinostat 20 mg orally OD, three times a week on days: 1, 3 and 5, then 8, 10 and 12, then 15, 17 and 19 of each cycle, as part of a 3-week (21 days) treatment cycle. Participants could continue treatment until disease progression or unacceptable toxicity.","id":"OG000","title":"Panobinostat"}],"paramType":"MEAN","populationDescription":"The analysis was performed in PAS population, defined as all participants who provide at least one post-dose PK plasma sample. Here, number of participants analyzed refer to the number of participants evaluable for this outcome at specified time point.","reportingStatus":"POSTED","timeFrame":"Pre-dose, 0.25, 1-2, and 3-4 hours post dose on Day 1 and Day 8","title":"Maximum Plasma Concentration (Cmax) of Panobinostat","type":"SECONDARY","unitOfMeasure":"ng/mL"}